National Institutes of Health: Lymphoma trials

The registry lists 362 Lymphoma studies with National Institutes of Health as lead sponsor. 15 are open to participants now and 130 have results posted.

Early Phase 1 2Phase 1 181Phase 2 171Phase 3 7Phase 4 1No phase 38(a study in two phases counts in both)

Studies

Page 3 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
• Lymphoma Follow-upCompletedNCT00744120
• Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
• Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00734890Phase 1
• Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver FunctionCompletedNCT00674024Phase 1
• SNX-5422 to Treat Solid Tumor Cancers and LymphomasCompletedNCT00644072Phase 1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or LymphomaCompletedNCT00589381Phase 1
• Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and LymphomasCompletedNCT00553189Phase 1
• Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• Safety of Batracylin in Patients With Solid Tumors and LymphomasCompletedNCT00450502Phase 1
• Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell LymphomaCompletedNCT00430053
• Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's LymphomaWithdrawnNCT00389506Not applicable
• ABT-888 in Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00387608Phase 1
• Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00377104Phase 1
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• Agriculture Health StudyActive, not recruitingNCT00352924
• PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
• Interdisciplinary Case-Control Study of Non-Hodgkin's LymphomaCompletedNCT00341952
• Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
• Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1CompletedNCT00339638
• CDDO to Treat Solid Tumors and LymphomasCompletedNCT00322140Phase 1
• Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
• Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
• Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00278382Phase 2
• Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver FunctionCompletedNCT00275093Phase 1
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
• Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System LymphomaCompletedNCT00226304
• Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
• Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or LymphomaCompletedNCT00088868Phase 1
• Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaCompletedNCT00085150Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's LymphomaCompletedNCT00082303Phase 1/2
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated LymphomaCompletedNCT00068146
• Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal SkinCompletedNCT00066664Not applicable
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine TherapyCompletedNCT00047164Phase 1
• UCN-01 and Prednisone in Treating Patients With Solid Tumors or LymphomaCompletedNCT00045500Phase 1
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaTerminatedNCT00036855Phase 1
• CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00033267Phase 2
• CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous TherapyCompletedNCT00031941Phase 1
• Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00026910
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWithdrawnNCT00024115Phase 1
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00022581Phase 2
• Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related LymphomaCompletedNCT00022555Phase 1
• MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular LymphomaCompletedNCT00020462Phase 1
• Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or LymphomaCompletedNCT00020111Phase 1
• Analysis of Genes Present in Cutaneous T-cell Lymphoma CellsCompletedNCT00020072Not applicable
• UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaCompletedNCT00019838Phase 1
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or LymphomasCompletedNCT00019513Phase 1
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• Depsipeptide in Treating Patients With Solid TumorsCompletedNCT00019318Phase 1
• Monoclonal Antibody Therapy in Treating Patients With LeukemiaCompletedNCT00019227Phase 1/2
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
• Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaCompletedNCT00018954Phase 2